Compare ASTS & NBIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASTS | NBIX |
|---|---|---|
| Founded | 2019 | 1992 |
| Country | United States | United States |
| Employees | 1126 | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.5B | 15.5B |
| IPO Year | 2019 | 1996 |
| Metric | ASTS | NBIX |
|---|---|---|
| Price | $57.39 | $141.13 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 14 | 28 |
| Target Price | $79.61 | ★ $208.40 |
| AVG Volume (30 Days) | ★ 7.8M | 978.0K |
| Earning Date | 11-09-2026 | 10-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 41.95 |
| EPS | N/A | ★ 3.30 |
| Revenue | $4,400,000.00 | ★ $161,626,000.00 |
| Revenue This Year | $138.08 | $36.49 |
| Revenue Next Year | $285.43 | $16.51 |
| P/E Ratio | ★ N/A | $41.88 |
| Revenue Growth | N/A | ★ 977.51 |
| 52 Week Low | $49.31 | $122.14 |
| 52 Week High | $133.86 | $186.12 |
| Indicator | ASTS | NBIX |
|---|---|---|
| Relative Strength Index (RSI) | 42.81 | 38.83 |
| Support Level | $54.78 | $125.18 |
| Resistance Level | $67.20 | $142.82 |
| Average True Range (ATR) | 3.27 | 3.63 |
| MACD | 0.01 | -0.24 |
| Stochastic Oscillator | 7.13 | 27.51 |
AST SpaceMobile Inc is currently designing, developing and manufacturing the constellation of BlueBird (BB) satellites and has begun launching its planned space-based Cellular Broadband network distributed through a constellation of low Earth orbit (LEO) satellites. The company is building a cellular broadband network in space to operate directly with standard, unmodified mobile devices, and off-the-shelf mobile phones based on extensive IP and patent portfolio. It has focused on eliminating the connectivity gaps faced by mobile subscribers. The Company's spaceMobile Service is being designed to provide cost-effective, high-speed Cellular Broadband services to end-users who are out of terrestrial cellular coverage using existing mobile devices.
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.